Phibro Animal Health Corporation’s (PAHC) growth in the fiscal first quarter of 2025 is backed by sustained improvement in the Animal Health business. The company’s focus on advancing vaccine technologies instills optimism. A rebound of Mineral Nutrition and Performance Product businesses seems encouraging. Yet, adverse macroeconomic impacts are a concern for Phibro’s operations.In the past year, this Zacks Rank #2 (Buy) company’s shares have rallied 107.9% compared with the industry’s 20.9% growth and the ...